Reach Us +1-504-608-2390
Lipid-lowering Strategies And Reduction Of Coronary Heart Disease Risk In Primary Care | 7914
ISSN: 2155-9880

Journal of Clinical & Experimental Cardiology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Lipid-lowering strategies and reduction of coronary heart disease risk in primary care

International Conference & Exhibition on Clinical Research Dermatology, Ophthalmology & Cardiology

Ersin Ekpinar

ScientificTracks Abstracts: JCEC

DOI: 10.4172/2155-9880.S1.01

Coronary heart disease (CHD) was the leading cause of death in the United States for both men and women. Stroke was the third leading cause of death and is a leading cause of severe, long-term disability among adults in the United States. Studies have shown a relation between dyslipidemia and CHD for several decades and lowering of low-density lipoprotein cholesterol (LDL-C) with statins has become part of the standard treatment regimen in patients with established CHD. Despite efficacy of current standards of care (including achievement of LDL-C, blood pressure and blood sugar goals), patients with atherogenic dyslipidemia which is common in patients with diabetes mellitus, metabolic syndrome or cardiovascular diseases remain exposed to a high residual risk of major cardiovascular vents and micro vascular complications. Satin therapy does not adequately address vascular risk associated with elevated triglycerides and low HDL-C levels. As studies shows, the addition of lipid modifying activity of fenofibrate to statin therapy benefited only certain subgroups of patients at increased cardio metabolic risk. Although, there is still under treatment with statins, especially in patients with CV disease. Less than 50% of patients were on target for LDL-cholesterol. Patients who do not achieve thresholds for statin therapy, but who are otherwise at high risk fo r cardiovascular. Events, should nonetheless receive statin therapy.
Ersin AKPINAR has completed his MD at the University of Cukurova and studying at the Family Medicine Department since 1999. He is the Editor- in-Chief of journal of TIPMED and has published more than 70 papers in reputed journals. He is the director of University outpa tient clinics